Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AVEO Pharma Q3 Loss Widens; To Cut Jobs - Quick Facts

RELATED NEWS
Trade AVEO now with 

AVEO Pharmaceuticals Inc. (AVEO: Quote) reported that its third-quarter net loss widened to $30.1 million, or $0.69 per share, from $23.8 million, or $0.55 per share, for the third quarter of 2011.

Total collaboration revenue for the third quarter of 2012 was approximately $1.0 million compared with $3.6 million for the third quarter of 2011. The decrease was due to revenue recognized in the third quarter of 2011 under AVEO's collaboration agreement with OSI that did not recur during the third quarter of 2012.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.87 per share on revenues of $6.57 million for the quarter. Analysts' estimates typically exclude special items.

The company updated its financial guidance that it expects to end 2012 with approximately $135 million in cash, cash equivalents and marketable securities. Based on its revised operating plan, AVEO anticipates that this capital is sufficient to fund its operations through 2013.

In addition, the company plans to explore further development of ficlatuzumab and certain discovery assets through external collaborations, including with academic partnerships and cooperative groups. The company plans to focus its Human Response Platform and discovery capabilities on supporting the clinical development of tivozanib, advancing biomarker identification and development across AVEO's clinical stage programs, and developing novel, high potential programs.

The company strategic restructuring and projected cost savings are being achieved through a combination of reduced spending on early stage research programs and a reduction in force of approximately 45 positions, or 17% of AVEO's workforce, as well as elimination of 30 open positions.

This refocusing of resources and reduction of expenses is expected to provide AVEO approximately $100 million in cost savings over the next three years compared with prior projections, with approximately $37 million in 2013, and is expected to extend its cash runway through 2013.

Register
To receive FREE breaking news email alerts for AVEO Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Looking to increase pressure on Congress, the White House released a report on Tuesday warning of the economic costs of delaying action to address climate change. With the August recess looming, House Republican leaders are hopeful they can pass legislation to address the crisis along the U.S.-Mexico border before the end of the week. The House is expected to vote on a bill providing $659 million in funding for the border crisis, well below the $3.7 billion requested by the Obama administration. After moving mostly higher in early trading on Tuesday, stocks have given back ground over the course of the trading session. A negative reaction to news of new European sanctions against Russia contributed to the pullback by the markets.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.